JOP20200075A1 - طرق لعلاج حالات عدوى بكتيرية - Google Patents

طرق لعلاج حالات عدوى بكتيرية

Info

Publication number
JOP20200075A1
JOP20200075A1 JOP/2020/0075A JOP20200075A JOP20200075A1 JO P20200075 A1 JOP20200075 A1 JO P20200075A1 JO P20200075 A JOP20200075 A JO P20200075A JO P20200075 A1 JOP20200075 A1 JO P20200075A1
Authority
JO
Jordan
Prior art keywords
undergoing treatment
treated
transplant
patient
bone marrow
Prior art date
Application number
JOP/2020/0075A
Other languages
English (en)
Inventor
Jeff Loutit
Elizabeth Alexander
Michael N Dudley
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65994826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200075(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of JOP20200075A1 publication Critical patent/JOP20200075A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

تتضمن طرق لعلاج عدوى بكتيرية في خاضعين للعلاج منقوصي المناعة وخاضعين للعلاج مصابين بواحد أو أكثر من الأورام الخبيثة الكامنة إعطاء توليفة من ميروبينيم و?ابورباكتام إلى الخاضع للعلاج. وقد يتضمن الخاضعون للعلاج المناسبون خاضعًا للعلاج له تاريخ للإصابة بلوكيميا أو ليمفومة مستمرة، وخاضعًا للعلاج قد مر بعملية زراعة أعضاء، أو زراعة خلايا جذعية، أو زراعة نخاع عظمي، أو استئصال الطحال، وخاضعًا للعلاج يتلقى أدوية كابتة للمناعة، وخاضعًا للعلاج يتلقى أدوية علاج كيماوي تفصل النخاع العظمي، وخاضعًا للعلاج يعاني من قلة العدلات وخاضعًا للعلاج يعاني من أو قد عانى من ورم خبيث. الشكل 1
JOP/2020/0075A 2017-10-03 2018-10-01 طرق لعلاج حالات عدوى بكتيرية JOP20200075A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567702P 2017-10-03 2017-10-03
US201862657402P 2018-04-13 2018-04-13
PCT/US2018/053772 WO2019070591A1 (en) 2017-10-03 2018-10-01 METHODS OF TREATING BACTERIAL INFECTIONS

Publications (1)

Publication Number Publication Date
JOP20200075A1 true JOP20200075A1 (ar) 2020-04-30

Family

ID=65994826

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0075A JOP20200075A1 (ar) 2017-10-03 2018-10-01 طرق لعلاج حالات عدوى بكتيرية

Country Status (16)

Country Link
US (2) US11376237B2 (ar)
EP (1) EP3691652A4 (ar)
JP (1) JP2020536092A (ar)
KR (1) KR20200066664A (ar)
CN (1) CN111432821A (ar)
AU (1) AU2018345317B2 (ar)
BR (1) BR112020006658A2 (ar)
CA (1) CA3078238A1 (ar)
CL (1) CL2020000892A1 (ar)
JO (1) JOP20200075A1 (ar)
MX (1) MX2020003670A (ar)
MY (1) MY200934A (ar)
PH (1) PH12020550249A1 (ar)
SG (1) SG11202003009QA (ar)
TW (2) TW201922241A (ar)
WO (1) WO2019070591A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200075A1 (ar) 2017-10-03 2020-04-30 Melinta Therapeutics Inc طرق لعلاج حالات عدوى بكتيرية
US20240207292A1 (en) * 2021-03-24 2024-06-27 Trustees Of Tufts College Boronic acid compounds, compositions and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912363A (zh) 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
CN102188395B (zh) 2011-04-29 2012-12-05 石药集团中诺药业（石家庄）有限公司 一种更稳定的美罗培南注射剂及其制备方法
CN102335136B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种供注射用美罗培南药物组合物及其制备方法
CN102335137B (zh) 2011-08-02 2013-06-12 天津市嵩锐医药科技有限公司 一种含美罗培南的药物组合物
CN102525961B (zh) 2012-01-17 2013-02-13 山东罗欣药业股份有限公司 美罗培南组合物注射用粉针剂
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN103570718B (zh) 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
MX363678B (es) 2013-05-28 2019-03-29 Morphochem Aktiengesellschaft Fuer Komb Torische Chemie Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
JP6945452B2 (ja) * 2015-04-24 2021-10-06 レンペックス・ファーマシューティカルズ・インコーポレイテッド 細菌感染症の処置方法
PL3319609T3 (pl) 2015-07-09 2022-12-05 Washington University Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych
US9949995B2 (en) 2015-09-04 2018-04-24 Case Western Reserve University Compositions and methods of treating of bacterial infections with β-lactamase inhibitors
KR102768209B1 (ko) 2017-01-09 2025-02-18 멜린타 테라퓨틱스, 엘엘씨 세균 감염을 치료하는 방법
JOP20200075A1 (ar) * 2017-10-03 2020-04-30 Melinta Therapeutics Inc طرق لعلاج حالات عدوى بكتيرية

Also Published As

Publication number Publication date
CA3078238A1 (en) 2019-04-11
TW201922241A (zh) 2019-06-16
EP3691652A4 (en) 2021-07-07
AU2018345317B2 (en) 2024-10-24
MX2020003670A (es) 2020-08-03
BR112020006658A2 (pt) 2020-09-24
AU2018345317A1 (en) 2020-05-07
SG11202003009QA (en) 2020-04-29
JP2020536092A (ja) 2020-12-10
US20200297695A1 (en) 2020-09-24
KR20200066664A (ko) 2020-06-10
WO2019070591A1 (en) 2019-04-11
TW202400146A (zh) 2024-01-01
US11376237B2 (en) 2022-07-05
US20220288024A1 (en) 2022-09-15
US12533342B2 (en) 2026-01-27
PH12020550249A1 (en) 2021-02-15
CN111432821A (zh) 2020-07-17
EP3691652A1 (en) 2020-08-12
MY200934A (en) 2024-01-24
CL2020000892A1 (es) 2020-10-23

Similar Documents

Publication Publication Date Title
MY206748A (en) Antibodies that target hiv gp120 and methods of use
PH12019500892A1 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
PH12017501300A1 (en) Novel iodophor composition and methods of use
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
PH12021552135A1 (en) Methods of treating al amyloidosis
EA202290048A1 (ru) Лекарственное средство и его применение для лечения бактериальных инфекций, связанных с биопленкой
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
JOP20200075A1 (ar) طرق لعلاج حالات عدوى بكتيرية
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
Nielsen First report of Actinomyces europaeus bacteraemia result from a breast abscess in a 53-year-old man
PH12021551805A1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2024005220A (es) Endoxifeno para el tratamiento del cancer.
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
MA53909B1 (fr) Compositions et méthodes de stimulation ovarienne contrôlée
MX2022011027A (es) Composiciones y metodos para el tratamiento del cancer.
PH12020551185A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
JOP20230172A1 (ar) طريقة لعلاج الداء النشواني al
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.